Advertisement

Topics

Latest "At Pappas Ventures" News Stories

04:17 EST 13th December 2018 | BioPortfolio

Here are the most relevant search results for "At Pappas Ventures" found in our extensive news archives from over 250 global news sources.

More Information about At Pappas Ventures on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about At Pappas Ventures for you to read. Along with our medical data and news we also list At Pappas Ventures Clinical Trials, which are updated daily. BioPortfolio also has a large database of At Pappas Ventures Companies for you to search.

Showing "Pappas Ventures" News Articles 1–25 of 1,100+

Wednesday 12th December 2018

Computer Aided Biology Pioneer Synthace Secures $25.6 Million in Series B Funding

Funding will be used to further expand product capabilities and fuel company growth Industry-leader is bringing software abstraction and automation to biological R&D and manufacturing Synthace Ltd., the company behind the leading cloud software platform for automating and improving the success rate of biolo...


Frank S. Czerwiec, M.D., Ph.D. joins Goldfinch Bio as Chief Medical Officer

Provides Global Clinical Development Expertise to Advance GFB-887 and Pipeline of Innovative Kidney Disease Treatments Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-driven kidney diseases, today announced the appointment of Frank S. Czerwiec, M.D., Ph.D. as Ch...

Checkmate Pharmaceuticals Announces CEO Transition and $22 Million Financing

Expanded Leadership Team and Funding Supports Advancement of Clinical Development of Checkmate’s TLR9 Agonist, CMP-001 Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat advanced cancer, has appointed Barry Labinger as President and CEO. Arthur M. Krieg, MD, Checkmate’s fou...


Casma Therapeutics Strengthens Leadership Team with Appointment of Chief Operating Officer, Vice President of People & Culture

Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointment of two senior executives who will help lead Casma through its next phase of growth. Caren Block, Casma’s new vice president of people & culture, has extensive experience in developing ...

InterVenn BioSciences Raises $9.4 Million to Help Physicians Detect Early Ovarian Cancer With a Minimally Invasive Test

Funding to accelerate InterVenn’s development of its AI-driven mass spectrometry platform that measures glycoproteomic markers that have been strongly linked to tumor development and progression. InterVenn BioSciences, a life sciences and technology company developing an AI-driven mass spectrometry platform, announced today an institutional investmen...

EIT Health Looks to Create New Business Ventures Addressing the Way we Manage Mental and Brain Health and Use Digital Biomarkers for Diagnostics

EIT Health, a network of best-in-class innovators backed by the EU, has announced the second year of its innovation programme, Wild Card. The second year of high-risk innovation programme Wild Card kicks off this week, challenging talent to deliver real solutions to the healthcare market.

Versant Ventures launches new biotech firm Black Diamond Therapeutics

Black Diamond is the first company launched out of Ridgeline, Versant’s Discovery Engine based in Basel, Switzerland, and has a unique platform capable of prosecuting allosteric mutant oncogenes. The post Versant Ventures launches new biotech firm Black Diamond Therapeutics appeared first on Pharmaceutical Business review.

Tuesday 11th December 2018

Dr. John Houston of Arvinas Named 2018 BioCT Entrepreneur of the Year

In a ceremony December 11 at the BioCT Annual Bioscience Holiday Celebration & Networking Party in New Haven, the 2018 BioCT Entrepreneur of the Year award was presented to Dr. John Houston of Arvinas, a biotechnology executive whose work has positively affected bioscience in Connecticut and beyond. Dr. Houston is President and CEO of Arvinas,...

WhiteSwell closes $30mm Series B

Cardiovascular-focused WhiteSwell raised $30mm in its Series B financing led by RA Capital Management and an InCube Ventures ...

@AJ_biotecsponge Allison Johnson

It turns out handfuls of allosteric mutant oncogenes are targetable with a single inhibitor. Read how newco Black Diamond Therapeutics – co-founded by leaders behind first-gen TKI Tarceva alongside Versant Ventures – will identify and drug these mutations:https://www.biocentury.com/bc-innovations/emerging-company-

Digital diagnostic lab co EfA raises $900,000

Engineering for All has become the 8th portfolio company in the eHealth Ventures technological incubator.

Black Diamond Emerges with $20M, Aiming for Cancer’s Hidden Targets

Nearly two years ago, Versant Ventures used some of its new $400 million fund to set up a drug discovery unit in Europe. The goal was to produce drugs and technology to spin out into independent companies. The first to launch from that effort, Black Diamond Therapeutics, has just emerged with an unusual approach to […]

Clustermarket Taps in to GE Healthcare Life Sciences Customers to Reach UK Innovators

Clustermarket, the leading UK online scientific equipment sharing and booking platform, has enlisted the support of GE Healthcare’s Life Sciences business in an agreement aimed at helping innovators in the UK access specialized life sciences and biotech equipment. LONDON (PRWEB) December 11, 2018 Clustermarket’s platform will allow owners of GE Healthcare Life Sciences instruments to hire out...

Versant Ventures Launches Black Diamond Therapeutics

Next-wave precision oncology company emerges from Versant’s Ridgeline Discovery Engine Black Diamond Therapeutics, a biotechnology company developing a new type of precision medicine for cancer, came out of stealth mode today with a $20 million Series A financing exclusively from founding investor Versant Ventures. Black Diamond is the first company ...

WhiteSwell Announces $30 Million Financing for New Therapeutic Approach to Acute Decompensated Heart Failure

Funds Will Support Product Development and Clinical Studies of Novel Catheter-Based Technology WhiteSwell, a company pioneering new ways to treat acute decompensated heart failure, today announced the close of a $30 million series B funding round led by RA Capital Management and an InCube Ventures syndicate, with participation from other investors. Fun...

Should the healthcare sector take a cue from software startups?

Gyan Kapur, Vice-President of Activate Ventures, has a playbook for bringing a touch of startup efficiency to healthcare companies. Here’s a look inside his firm’s investment thesis.

US Court of Appeals Upholds Gilenya Compound Patent, Dealing A Blow To Ezra Ventures

Upholding the validity of Novartis’ Gilenya compound patent, a US Court of Appeals ensures that US-based Ezra’s generic fingolimod hydrochloride...  

Monday 10th December 2018

Millendo gets $49.5mm in financing concurrent with OvaScience merger closing

Concurrent with the closing of its reverse merger with OvaScience Inc., Millendo Therapeutics Inc. raised $49.5mm in a financ...

ALung Announces Significant Progress in its Hemolung Clinical Trial Programs

ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the achievement of major milestones in its clinical trial programs. In the United States, nearly thirty hospitals have been brought online for ALung’s VENT-AVOID Trial...

Bay Labs Announces Collaboration with Edwards Lifesciences to Utilize AI Software to Improve Heart Disease Detection

Bay Labs, a medical technology company at the forefront of applying artificial intelligence (AI) to cardiovascular imaging, announced today a collaboration with Edwards Lifesciences focused on improving the detection of heart disease. The partnership involves multiple initiatives, including the development of new AI-powered algorithms in Bay Labs’...

Friday 7th December 2018

XyloCor gets $17mm in Series A financing

Gene therapy developer XyloCor Therapeutics Inc. raised $17mm in its Series A financing led by Sofinnova Ventures and LSP, wh...

Healthcare Innovator Ronald Amodeo Joins Dorsey Health Strategies in Minneapolis

International law firm Dorsey & Whitney LLP is pleased to announce that Ronald Amodeo has joined the Firm as an Expert Advisor with Dorsey Health Strategies (DHS), a healthcare consulting firm affiliated with Dorsey & Whitney. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181207005541/en/ ...

Thursday 6th December 2018

Viracta raises $18.4mm in Series B round

Viracta Therapeutics Inc. (therapies for virus-based cancers) closed the first tranche of its $18.4mm Series B round. NantKwe...

Casma Therapeutics Licenses Technology to Advance Autophagy-Based Drug Discovery

Casma Therapeutics, Inc. today announced an exclusive and nonexclusive license to technology developed at The University of Texas Southwestern Medical Center that will advance the company’s drive to harness the natural cellular processes of autophagy to design powerful new medicines for a broad range of diseases. The license includes...

Lightpoint Medical Secures £5 Million for Product Commercialization

Lightpoint Medical, a leader in intraoperative molecular imaging and sensing, announced today that the company has secured £5 million in equity finance to fuel the company’s commercial growth. Investors included existing and new shareholders Cambridge Capital Group, Venture Founders, Coutts Investment Club, Envestors, Fund Twenty8, SyndicateRoom, and Ox...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks